Beyond the black box: Drug- and device-associated hypersensitivity events

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 1-5

  Bennett, Charles L ^a,b   Adegboro, Olatokunbo S ^b   Calhoun, Elizabeth A ^b   Raisch, Dennis ^c,d  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d Clinical Research Pharmacy   (United States)

Author keywords

Adverse events; Drug; Hypersensivity; Toxicity

Indexed keywords

CREMOPHOR; NEVIRAPINE; PACLITAXEL; RAPAMYCIN;

ACUTE DISEASE; ADVISORY COMMITTEE; ANAPHYLAXIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DISEASE COURSE; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG FATALITY; DRUG INFORMATION; DRUG PACKAGING; DRUG SURVEILLANCE PROGRAM; HEART ARREST; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; INFORMATION DISSEMINATION; OCCUPATIONAL EXPOSURE; RESPIRATORY FAILURE; REVIEW; SAFETY; STEVENS JOHNSON SYNDROME;

EID: 77953365621     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s6548     Document Type: Review

References (20)

1. Food and Drug Administration. Information for Physicians on Sub-Acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER Coronary Stent. FDA Public Health Web Notification. 1st edition. Rockville, MD: Food and Drug Administration; 2003. p. 2.
2. Sicherer SH, Leung DYM. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008. J Allergy Clin Immunol. 2009;123:319-327.
3. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765-2768.
4. Gurtcheff SE. Introduction to the MAUDE database. Clin Obstet Gynecol. 2008;51:120-123.
5. Bennett CL, Nebeker JR, Lyons A, et al. The research on adverse drug events and reports (RADAR) project. JAMA. 2005;293:2131-2140.
6. Bennett CL, Nebecker JR, Yarnold PR, et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007;167:1041-1049.
7. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-181.
8. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine-containing anti-retroviral regimen. Ann Intern Med. 2002;137:146-147.
9. Bennett CL, Raisch DW, Sartor O. Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. Ann Intern Med. 2002;137:625.
10. Food and Drug Administration. Public health Web notification: Information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER coronary stent. Silver Spring, MD: US Food and Drug Administration; October 29, 2003.
11. Food and Drug Administration. Public health Web notification: Updated information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER sirolimus-eluting coronary stent. Silver Spring, MD: US Food and Drug Administration; November 25, 2003.
12. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-1598.
13. Lorenz A, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents Actions. 1977;7:63-67.
14. Ramanathan RK, Belandri C. Transient pulmonary infiltrates: A hypersensitivity reaction to paclitaxel. Ann Intern Med. 1996;124:278.
15. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
16. Benn PD, Mercey DE, Brink N, Scott G, Williams IG. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet. 2001;357:687-688.
17. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
18. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001;49:1153-1156.
19. Carbarns IRI, Hudson AJ, Wang R, Arnold B. Use of risk management planning to enhance safety of medicines. Int J Pharm Med. 2007;21:415-426.
20. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009;150:516-527.